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Abstract
Background: The objective of the present study was to explore the benefits of Porcine circovirus 2 (PCV-2) blanket
vaccination in a sow herd on productive parameters, PCV-2 infection and immune status in sows and their
progeny. For this purpose, 288 sows were distributed among four balanced experimental groups. One group
remained as negative control group and the other three received 1 mL of PCV-2 Ingelvac Circoflex® intramuscularly
at different productive cycle moments: before mating, mid gestation (42–49 days post-insemination) or late
gestation (86–93 days post-insemination); phosphate buffered saline (PBS) was used as negative control item.
Reproductive parameters from sows during gestation and body weight of their progeny from birth to weaning
were recorded. Additionally, blood was collected from sows at each vaccination time and piglets at 3 weeks of age.
Moreover, up to 4 placental umbilical cords (PUC) per sow were taken at peri-partum. Sera from sows and piglets
were analysed for PCV-2 antibody detection using an enzyme-linked immunosorbent assay (ELISA). Sera from sows
and PUC were tested to quantify viraemia using a real time quantitative polymerase chain reaction (qPCR) assay.
Results: Globally, results indicated that vaccinated sows showed heavier piglets at birth and at weaning, less cross-
fostered piglets, lower viral load at farrowing as well as in PUC, and higher antibody levels at farrowing, compared
to non-vaccinated ones. When all groups were compared among them, sows vaccinated at mid or late gestation
had heavier piglets at birth than non-vaccinated sows, and lower proportion of PCV-2 positive PUC. Also, cross-
fostering was less frequently practiced in sows vaccinated at pre-mating or mid gestation compared to non-
vaccinated ones.
Conclusions: In conclusion, the present study points out that PCV-2 sow vaccination at different time points of
their physiological status (mimicking blanket vaccination) offers benefits at production and serological and
virological levels.
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Background
Porcine circovirus 2 (PCV-2) is a small, circular, non-
enveloped, single-stranded DNA virus of 20 nm in diam-
eter approximately, belonging to the genus Circovirus,
family Circoviridae [1]. This virus is ubiquitous in the
pig population [2–6] and is the etiologic agent of clinical
diseases and subclinical infection comprised under the
term of porcine circovirus diseases [7].
Intrauterine PCV-2 infections in different stages of
pregnancy may cause different reproductive disorders
depending on the foetal immunological competence [8],
the so-called PCV-2 reproductive disease. Intrauterine
PCV-2 infection of foetuses, via insemination or trans-
placental, may cause late-term abortions, mummified,
stillborn and weak born piglets [9–14]. Furthermore,
pigs may be born PCV-2 viraemic due to transplacental
infection that may subsequently act as an infection focus
for their pen mates. All these situations imply that in-
fected sows have a very important role in PCV-2 infec-
tion maintenance and dissemination in the herd due to
horizontal and vertical infection transmission.
Nowadays, vaccination is a very effective tool to con-
trol PCV-2 infection. From 2007 to present, four major
PCV-2 vaccines have been marketed worldwide [15], but
only two are licensed in several countries for their use in
sows to protect their progeny. Therefore, current prod-
ucts allow applying different vaccination regimes com-
bining piglet and/or sow vaccination [16, 17]. These
abovementioned vaccines are an inactivated PCV-2a vac-
cine, a recombinant vaccine based on an inactivated
PCV-1/PCV-2a chimeric virus or subunit vaccines based
on a PCV-2a Cap protein. Specifically, the vaccine tested
in this study, Ingelvac Circoflex®, is a PCV-2a subunit
vaccine based on the product of the ORF2 gene
expressed in a baculovirus system [15]. However, cross-
protection between the major genotypes worldwide
(PCV-2a, PCV-2b and PCV-2d) has been observed in ex-
perimental trials and field studies [18–20].
Different studies have shown the capacity of the sow
vaccination to induce an immune response and the trans-
fer of passive immunity to the offspring. Sow vaccination
before mating stabilizes and homogenizes the PCV-2 im-
mune status of the sow population during gestation [21–
24]. Sow vaccination administered before farrowing can
confer protection through maternally derived immunity to
their offspring against PCV-2 systemic disease by reducing
viraemia [16], lesions and viral load in tissues [25] as well
as increasing their average daily weight gain in PCV-2
subclinical infection [22]. When this vaccination strategy
is boosted in the following reproductive cycles at 3 weeks
before farrowing (for 3 years), an improvement of the
reproduction rate, number of piglets born alive, birth
weight of piglets and number of piglets weaned per a litter
was achieved [26]. Another study, where the boost was
applied on the second cycle at 2 weeks before farrowing,
reported higher number of live-born piglets per litter at
the second cycle and higher vitality score from the fist
cycle [13] compared to the non-vaccinated (NV) group.
Nevertheless, the effect of PCV-2 sow vaccination strat-
egies on reproductive parameters has been, up to now,
scarcely studied [13, 26]. Furthermore, practices in the
field have explored the option of sow blanket vaccination
(personal communication of field veterinarians); however,
no contrasted data has been scientifically described.
Hence, the objective of the present work was to evalu-
ate the effects of sow vaccination against PCV-2 applied
at different stages of the production cycle (before mat-
ing, mid gestation and late gestation), mimicking a blan-
ket vaccination fashion, on productive parameters as




Productive parameters from gilts/sows and piglets from
the three vaccinated (V) groups taken together and the
non-vaccinated (NV) group are shown in Table 1. The
comparison of these parameters among each treatment
group are detailed in Table 2. In both tables, statistically
significant differences and tendencies are indicated.
PCV-2 antibody values in serum samples of sows and
piglets
PCV-2 IgG and IgM ELISA optical density (OD) values of sows
Sow blood samples collected at the three vaccine/PBS
application times as well as at farrowing were used to
determine the dynamics of IgG antibodies against PCV-
2 (Fig. 1). Each of the different V treatments showed sig-
nificantly higher IgG values than the NV group from the
sampling after their vaccine application until farrowing.
At this point, no statistically significant differences be-
tween sows vaccinated at mid (V MG) and late (V LG)
nor between sows vaccinated at pre-mating (V PM) and
V MG group were observed.
In general terms, the PCV-2 IgM OD values of the
four groups were very low (mean OD values between
0.40 ± 0.14 and 0.51 ± 0.20 at the different sampling
points, data not shown) and no statistical differences in
OD values between each experimental group at any time
point were found.
PCV-2 IgG ELISA S/P values of weaned pigs
Blood samples from 4 to 6 randomly selected piglets per
each sow were taken at weaning and used to detect
PCV-2 antibodies. Mean PCV-2 S/P values per treatment
groups are represented in Fig. 2. Piglets from V sows
showed significantly higher PCV-2 S/P values than
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piglets from NV sows. The highest values were obtained
in piglets from V MG and V LG sows.
qPCR to detect PCV-2
PCV-2 DNA in sow serum samples
Blood samples from sows taken at the three vaccine/PBS
application times as well as at farrowing were used to
assess the proportion of PCV-2 qPCR positive sera from
V and NV animals (Table 3).
Only three sows were positive to qPCR through the
study: One V animal from V PM group was positive at
mid gestation sampling point (104.2 PCV-2 copies/mL),
and two NV sows were positive at farrowing (one with
105.3 PCV2 copies/mL and another one below the limit
of quantification (LOQ = 104.00 PCV-2 genome copies/
Table 1 Productive parameters (mean ± SD or proportion [percentage] plus confidence interval [CI]) of V and NV sows
V NV
Total born piglets /sow 14.1 ± 3.0a 13.6 ± 3.6a
Live born piglets/sow 13.4 ± 3.0a 12.9 ± 3.7a
Weaning-to-mate interval (days) 4.6 ± 5.1a 4.6 ± 5.0a
Weaning-to-fecundation interval (days) 30.7 ± 7.0a 30.2 ± 5.3a





















Piglets birth weight (Kg) 1.64 ± 0.39a 1.58 ± 0.38b
Weaned piglet weight (Kg) 6.51 ± 1.48a 6.37 ± 1.48b
Different letters in superscript in a row indicate significant differences (p ≤ 0.05) between V and NV groups (highlighted in bold)
V Vaccinated, NV Non-vaccinated
Table 2 Productive parameters (mean ± SD or proportion [percentage] plus CI) of the four studied experimental groups
V PM V MG V LG NV
Total born piglets /sow 14.1 ± 2.8a 13.9 ± 2.5a 14.3 ± 3.5a 13.6 ± 3.6a
Live born piglets/sow 13.3 ± 2.7a 13.5 ± 2.6a 13.4 ± 3.6a 12.9 ± 3.7a
Weaning-to-mate interval (days) 4.2 ± 3.6a 4.7 ± 5.9a 4.8 ± 5.7a 4.6 ± 5.0a
Weaning-to-fecundation interval (days) 30.7 ± 7.7a 30.6 ± 6.7a 30.7 ± 6.6a 30.2 ± 5.3a









































Piglets birth weight (Kg) 1.62 ± 0.40a,b 1.66 ± 0.38a 1.64 ± 0.39a 1.58 ± 0.38b
Weaned piglet weight (Kg) 6.49 ± 1.50a 6.52 ± 1.48a 6.52 ± 1.45a 6.37 ± 1.48a
Different letters in superscript in a row indicate significant differences (p ≤ 0.05 for lower case letters) or tendency (p ≤ 0.10 for capital letters) among experimental
groups (highlighted in bold)
V PM Vaccinated pre-mating, V MG Vaccinated at mid gestation, V LG Vaccinated at late gestation, NV Non-vaccinated
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mL) with 103.9 PCV2 copies/ml). At farrowing sampling
point, a lower (p = 0.01) proportion of positive PCV-2
qPCR in serum was detected in V sows (0 out of 172)
compared to NV ones (2 out of 49).
PCV-2 DNA in serum samples from placental umbilical cord
pools
Blood from 3 (ranging 1 to 4) porcine umbilical cords
(PUCs) per sow were individually collected at farrowing to
quantify virus in serum samples. All these samples were
processed as a pool of 2–3 PUC sera/sow at farrowing (n =
171), except when only one PUC was collected (n = 13).
The number of PCV-2 qPCR positive pools of PUCs was
significantly lower (p = 0.01) in V sow groups (12/142 pools,
9% [CI: 3.9–13.0%]) compared to NV group (10/42 pools,
24% [CI: 10.9–36.7%]). When the comparison between each
experimental group was performed, animals from V LG
group had a significantly lower (p = 0.01) proportion of
PCV-2 qPCR positive pools of PUCs (2/45 pools, 4% [CI: −
1.6-10.5%]) compared to NV sows (10/42 pools, 24% [CI:
10.9–36.7%]). Additionally, a tendency (p = 0.08) in the pro-
portion of PCV-2 qPCR positive pools of PUCs were noted
in dams from V MG group (4/47 pools, 9% [CI: 0.5–
16.5%]) when compared to NV sows (10/42 pools, 24% [CI:
10.9–36.7%]). Moreover, a lower (p = 0.01) PCV-2 load in
PUC pools was observed in sows from the V groups (below
Fig. 1 PCV-2 IgG OD results (mean ± SD) form sows’ serum samples of the four experimental groups. V PM: vaccinated pre-mating; V MG:
vaccinated at mid gestation; V LG: vaccinated at late gestation; NV: non-vaccinated. Different letters indicate statistically significant differences
(p ≤ 0.05) among experimental groups for a given sampling point
Fig. 2 PCV-2 IgG S/P values (mean ± SD) from weaned piglets’ serum samples of each experimental group. V PM: vaccinated pre-mating; V MG:
vaccinated at mid gestation; V LG: vaccinated at late gestation; NV: non-vaccinated. Different letters indicate significant differences among
experimental groups (p≤ 0.05)
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limit of detection [LOD] [100.42 ± 101.43 PCV-2 genome
copies/mL]) compared to NV ones (below LOD [101.12 ±
102.11 PCV-2 genome copies/mL]). No statistically signifi-
cant differences were observed in PCV-2 load in PUC pools
when the comparison was done between each experimental
group by separate.
PCV-2 genotyping
PCV-2 ORF2 from serum and PUC samples with some of
the highest PCV-2 loads (between 104.19 and 108.06 PCV-2
genome copies/mL) were sequenced to ascertain the main
PCV-2 genotype/s circulating in the farm. Specifically, one
positive serum sample from the V PM group collected at
mid gestation sampling point and 7 individual PUC sam-
ples recovered from 3 pools (three from the NV, two from
the V MG and two from the V PM sow groups). The
phylogenetic tree including the relationships among the
ORF2 sequences determined in this study and reference
strains is presented in Fig. 3. Genotype PCV-2b was found
in the V PM sow serum sample from the mid gestation
sampling point (MT572494 S 4525) and in 3 PUC from
the same NV sow, all three with identical sequence
(MT572495 PUC 3978). These two sequences showed 99,
54% of nucleotide identity between them. Genotype PCV-
2d was found in two PUC from a V PM sow (both with
identical sequence, MT572497 PUC 4182) and in other
two PUC from a V MG sow (also with the same sequence,
MT572496 PUC 4035). These two sequences were identi-
cal between them as well.
Discussion
The present study deals with a poorly described topic such
as the effects of sow vaccination against PCV-2 on
Fig. 3 Phylogenetic tree derived from PCV-2 capsid protein (ORF2) sequences. The tree was constructed by using Maximum-Likelihood method
with 1000 bootstrap replicates. Bootstrap values higher than 70 are indicated. Sequences from this study are highlighted in red and labelled with
the accession number + PUC (for PUC samples) or S (for sow sample) + sow number
Table 3 Proportion of PCV-2 qPCR positive sera in sows and CI
from V and NV groups
Sampling point

















Different letters in superscript indicate significant differences (p ≤ 0.05) among
experimental groups
V Vaccinated, NV Non-vaccinated
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productive and infectious parameters of sows and their
progeny. To accomplish this task, sows and gilts were vac-
cinated at three different reproductive periods (before
mating, mid gestation and late gestation). When all the
vaccinated sow groups were joined (independently of the
moment of vaccine application), mimicking a blanket
fashion vaccination strategy, significant improvement of
productive parameters in terms of piglets’ weight at birth
and at weaning and cross-fostering practice reduction
were achieved. Moreover, a significant reduction in the
proportion of PCV-2 infected sows and their viral loads at
farrowing and in PUC were also observed when compared
to NV sows, although a low PCV-2 infection pressure was
detected. When the period of vaccine application was con-
sidered, a tendency in reduction of mummies in the V PM
group compared to NV one was observed.
Few published studies describe the benefits of sow vac-
cination on reproductive parameters under field condi-
tions. This is probably due to the low frequency of
reproductive disorders associated with PCV-2 [26], and
their rather unknown impact. Currently, only five peer-
reviewed published studies recorded reproductive pa-
rameters in vaccinated sow farms. In one study [22],
dams were vaccinated against PCV-2 at 4 and 2 weeks
before artificial insemination and 4 weeks pre-partum. In
another one [16], sows were vaccinated 1 week prior to
mating. In the third one [26], PCV-2 sow vaccination
was implemented for 3 years; dams were vaccinated at 6
and 3 weeks before farrowing in the first reproductive
cycle and boosted in the following reproductive cycles at
3 weeks before farrowing. In the fourth study [13], dams
were immunized against PCV-2 at 6 and 3 weeks pre-
farrowing on the first cycle and sows received a boost 2
weeks pre-farrowing on the second cycle. Finally, in the
last one [27], three groups of sows were PCV-2 vacci-
nated 1 day after weaning, 28 days after weaning and
non-vaccinated, respectively. In the present study, in
comparison with the abovementioned works, the sow
vaccination scheme considered PCV-2 vaccination at dif-
ferent reproductive time points in the same herd, resem-
bling a blanket fashion vaccination strategy.
In the present study, piglets from V sows showed a
significantly higher mean birth weight. Among all vac-
cination groups, the highest body weights were obtained
in piglets coming from V MG and V LG groups. Consid-
ering the short period between vaccination at late gesta-
tion and the delivery, the difference in weight between
piglets from V LG and NV groups was unexpected. This
result, however, would be similar to the one obtained in
one study in which sows were also vaccinated at late ges-
tation [26]. Moreover, the weight of weaned piglets (at 3
weeks of age approximately) coming from V sows was
higher compared to those from NV dams. These results
are in contrast with the ones of Fraile et al. [16], where
sows were vaccinated pre-mating and no differences
were observed in weaned piglet weight at 4 weeks of age.
Reasons for such differences may be attributable to the
different vaccine product or schedule used and/or lack
of power due to the limited sample size of the study.
Moreover, there are many inter-farm factors (animal
genetics, farm facilities, management practices, treat-
ments, nutrition and vaccination schedule) that may in-
fluence the vaccination outcome.
Piglets coming from V sows were significantly less
cross-fostered compared to the NV group; more specif-
ically, significantly less cross-fostering was performed in
V PM and V MG dams compared to the NV group.
Also, a tendency to practice less cross-fostering in pig-
lets from V MG dams was noted compared to that in V
LG sows. Cross-fostering is a practice frequently used to
increase piglet survival and to organize litters with uni-
form body weight [28]. However, biosecurity procedures
recommend minimizing the number of cross-fostered
animals [29]; therefore, reduction of this practice may
help diminishing PCV-2 transmission among piglets.
A tendency of a lower proportion of mummies was
observed in the V PM sow group compared with the NV
group. Considering that mummification is an outcome
of late reproductive problems [30], the potential benefits
of PCV-2 vaccination at pre-mating on mummies reduc-
tion was expected. This result is in contrast with Kur-
mann et al. [22] and Sibila et al. [24], where sows were
vaccinated pre-mating, and with Oliver-Ferrando et al.
[13], where sows were vaccinated at mid-late gestation.
Further studies with a higher number of tested sows
would be needed to confirm the data obtained herein.
In relation to stillborn, no statistical differences were
observed in the current study, in accordance with
Cybulski et al. study [27]. Oliver-Ferrando et al. [13]
found an inconsistent situation, where a higher number
of stillbirths/litter in the V group was observed in the
first reproductive cycle but not in the second one.
Nevertheless, proportions of stillborn detected in the
present study and in Oliver-Ferrando et al. [13] are
aligned with regular values expected in the average
Spanish pig farm (8.6%) according to national records
(www.bdporc.irta.es).
Although Oliver-Ferrando et al. [13] and Pejsak et al.
[26] reported an improvement in number of liveborn
piglets, in the present case only a positive (numerically,
but non-significant) effect was obtained similar to the
study of Kurmann et al. [22] and in 28 days after wean-
ing vaccination group from Cybulski et al. study [27].
In addition, no significant differences in the proportion
of abortions were detected in the present study similarly
to results obtained in Kurmann et al. study [22]. Consid-
ering the low frequency of abortions detected in the
present study, a larger sample size would be necessary to
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analyse this parameter and determine their effect. Never-
theless, the design of our study was not within the scope
of detecting the presence of significant differences for
this latter parameter.
Similarly, Pejsak et al. [26] and Oliver-Ferrando et al.
[13] detected a higher number of weaned piglets/litter (be-
ing only statistically significant in Pejsak) in V dams com-
pared to NV dams, respectively. These two latter studies
indicated that the repeated use of PCV-2 sow vaccination
can improve reproductive parameters. So, these positive
effects (piglets born alive and weaned piglets/litter) may
probably be more evident after several gestational cycles
vaccinating the sows against PCV-2 rather than one single
vaccination of sows as in the present study.
The antibody profile from sows immunized against
PCV-2 revealed seroconversion after each vaccination,
conferring a stronger herd immunity against PCV-2
compared to the NV [10, 13, 22, 24]. Besides, the NV
group maintained low ELISA OD values during all gesta-
tion period. In this sense, despite sow infection remained
low or non-detectable in all studied groups during the
gestation period, no V sows were found infected at far-
rowing while 4% of NV ones were qPCR positive. Al-
though significant differences at the farrowing period in
terms of percentage of viraemic sows was detected, the
number of PCV-2 qPCR positive sera in sows was low.
These results, however, should not be considered sur-
prising since the number of infected sows tend to be low
in most farms where subclinical infection is taking place
[8, 13, 31, 32]; moreover, batch differences may also ac-
count for certain variability. Therefore, further studies
would be desirable to further confirm this finding.
The virological results obtained in the study were in
fairly contrast with those obtained in the screening prior
to the start of the study, where PCV-2 DNA was detected
in serum samples from 18 out of 30 clinically healthy
sows. Moreover, PCV-2 genome was also detected in 24
out of 30 PUCs from the same sows. These initial results
would fit well with those observed by other research
groups in some PCV-2-SI farms in absence of vaccination
[33]. It is very likely that differences on percentage of in-
fected sows among batches and the PCV-2 vaccination in
¾ of the studied groups could explain the variability and
reduction of the PCV-2 infection pressure within the same
farm when the large study was carried out. It is speculated
that the reduction of the PCV-2 infection pressure prob-
ably caused a reduction of transplacental transmission of
PCV-2 to foetuses, evidenced by the lower proportion of
PUC PCV-2 qPCR positive samples and viral load de-
tected compared to the farm previous screening.
The higher antibody levels of V sows than NV ones at
farrowing suggests a higher transfer of maternally de-
rived antibodies (MDA) to piglets of V sows via colos-
trum as also described [16, 22, 34]. This scenario should
place piglets from V sows in a better immune position
to counteract PCV-2 infection at early ages [16]. As ex-
pected, the highest MDA transfer was observed in
weaned piglets from V MG and V LG groups, followed
by V PM. On the other hand, considering that all piglets
were vaccinated at 3 weeks of age against PCV-2, certain
concerns regarding MDA interference with vaccination
could arise. Although in this study MDA interference
with pig vaccination was not explored, several studies
have reported evidence of such interference with vaccine
humoral immune response [16, 35–38]. However, the ef-
ficacy of the same vaccine used in this study has not
shown to be jeopardized by high values of MDA [39].
Two PCV-2 genotypes, PCV-2b and PCV-2d, circulated
in the herd, being the most prevalent ones in the field
worldwide [40, 41]. The co-circulation of two or more
PCV-2 genotypes in the same farm is not unusual [42–
44]. Current vaccines based on PCV-2a strains appear to
be able to cope with major circulating strains worldwide
due to cross-protection among genotypes [3, 18–20].
PCV2 vaccines are the most sold preventive product
in the porcine industry and one of the biological
products in swine with highest return of inversion
[15]. Besides, the combined vaccination of sows and
piglets is an increasing practice since provides the op-
timal performance in animals [16, 45], and although
there is little information about gilt/sow
immunization, vaccination of pigs and sows has been
estimated cost-efficient [15]. However, each farm
should be analysed case by case to study the cost
/benefit of PCV-2 vaccination [46].
Conclusions
Vaccination of the breeding herd (gilts and sows) against
PCV-2, mimicking a blanket fashion schedule in a sub-
clinical infection scenario, improved immune status of
dams and the progeny against the virus and reduced
virus circulation at farrowing in sows and vertical infec-
tion to foetuses, although a low infectious pressure was
detected during the study. PCV-2 sow vaccination also
improved piglets’ weight at birth and at weaning and
reduced cross-fostering practice. Also, a tendency in
reduction of mummies from V PM group compared
to NV was observed. Due to the limited PCV-2 circu-
lation detected in the dams during the present ex-
ploratory study, the impact of PCV-2 vaccination on
the productivity was considered of low impact. Fur-




Inclusion criteria for farm selection were: a) sows/gilts
housed in a single conventional farm (site I), b) no PCV-
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2 vaccination schedule in gilts/sows, c) allowance of con-
trolled cross-fostering practices, and d) evidence of
PCV-2 infection by means of viral genome detection in
sows and PUCs in site I. Indeed, prior to the start of the
study, PCV-2 DNA was detected in serum samples from
18 out of 30 (60%, viral load range 103.50 and 107.91 gen-
ome copies/mL) clinically healthy sows from different
parity number and in 24 out of 30 (80%, viral load range
103.50 and 107.06. genome copies/ml) PUCs from the
same sows, indicating a PCV-2-SI scenario. Inclusion
criteria for gilts/sows selection were: a) healthy animals,
b) not pregnant, c) from the same genetic line, d) of all
parities (gilts, primiparous and multiparous).
The study was conducted in a two-site commercial
farm located in Catalonia (Spain). The farm had 1400
sows (including gilts) and used a weekly farrowing batch
system; piglet weaning was performed at 25 days of age
approximately. The farm was Mycoplasma hyopneumo-
niae positive, Porcine reproductive and respiratory syn-
drome virus (PRRSV) positive stable, and negative for
Aujeszky’s disease virus. Gilts and sows were crossbred
(Duroc x Landrace) and were artificially inseminated
with Pietrain boar semen. The vaccination routine of the
farm included gilt and sow immunization against
PRRSV, Porcine parvovirus, Erysipelothrix rhusiopathiae,
Escherichia coli and Clostridium perfringens. Piglets were
vaccinated against PCV-2 and Mycoplasma hyopneumo-
niae before weaning.
Study design
The present study was a parallel group, randomised and
controlled trial. The study was unmasked for personnel
involved in study design and monitoring, vaccine dispen-
sation and for personnel involved in body weight and
sample collection, whereas it was masked for farm
personnel (routine management, daily observation and
routine reproductive data recording) as well as for la-
boratory technicians. Study design is summarized in
Fig. 4. Sows were bled before mating and tested for
PCV-2 IgG and IgM ELISAs. Animals were randomly al-
located into 4 different treatment groups blocking by
parity (from 0 to 8) and OD values for PCV-2 IgG and
PCV-2 IgM. A total of 288 healthy sows were selected
through six consecutive breeding batches and distributed
in the following treatments groups: vaccination of 73 at
pre-mating (PM), 72 at mid gestation (MG), 73 at late
gestation (LG) and 70 were kept as NV sows. These
three specific immunization times were chosen to mimic
a blanket vaccination fashion, which is performed in
sows at all physiological status at a given time point.
Gestation was monitored until farrowing and then their
piglets were followed up until weaning. Sows from all
treatment groups were housed comingled during the
study (in same pens when they were housed in groups,
and in same room when they were individualized).
Cross-fostering of piglets was only allowed among sows
of the same experimental group.
All sows included in the study were injected (with
phosphate buffered saline [PBS] or PCV-2 vaccine) three
times before farrowing. Sows were vaccinated intramus-
cularly (neck muscle) with 1 mL of PCV-2 Ingelvac Cir-
coflex® or PBS. Blood samples from sows were collected
at the three vaccine/PBS application times as well as at
farrowing. Obtained sera were tested for PCV-2 IgG and
Fig. 4 Experimental study design, including sampling time points and PCV-2 vaccine/PBS application timing. V PM: vaccinated at pre-mating; V
MG: vaccinated at mid gestation; V LG: vaccinated at late gestation; NV: non-vaccinated; AI: artificial insemination; PCV-2 vaccine: 1 mL of PCV-2
Ingelvac Circoflex®; PBS: phosphate buffer saline
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IgM antibodies using a commercial ELISA assay and to
quantify virus using a qPCR assay. At pre-mating sam-
pling point, PCV-2 IgG and IgM ELISA assay was per-
formed in 288 sow sera to randomize the sows in 4
experimental groups. ELISA assay from mid gestation,
late gestation and farrowing sampling points and qPCR
assay from the fourth sampling points were performed
only in those artificially inseminated sows (Additional
file 1). Blood from 3 (ranging 1 to 4) PUCs per sow were
individually collected at farrowing to quantify virus in
serum samples using the qPCR assay. In order to
minimize PCV-2 environmental contamination, gloves
were changed, and scissors were disinfected with ethanol
for each PUC sampling. Additionally, productive param-
eters from gilts/sows and piglets were recorded (de-
scribed in section 7). Moreover, at weaning, sera
samples from 4 to 6 randomly selected piglets per each
sow were taken and used to detect PCV-2 antibodies
using an ELISA test.
Once in the laboratory, blood samples were centri-
fuged at 2500 rpm (1300 g) during 10 min at 4 °C to ob-
tain sera. All sera were stored at − 20 °C until testing.
DNA extraction and qPCR
Presence of PCV-2 DNA by qPCR was assessed in the
serum samples from sows and PUCs. All these samples
were processed by pools. Indeed, pools from 2 to 3 sow
serum samples at each sampling point and pools of 2–3
PUC sera per sow at farrowing (except when only one
PUC was collected) were created. When a pool from
sow sera was qPCR positive, individual serum samples
were tested by qPCR following the same protocol.
DNA was extracted from 200 μL of serum (from sows)
or pool by using the MagMAX™ Pathogen RNA/DNA Kit
(Thermo Fischer Scientific Baltics. Vilnius, Lithuania) fol-
lowing the manufacturer’s instructions. To quantify the
PCV-2 DNA in serum samples, a qPCR assay (LSI Vet-
MAX™ Porcine Circovirus Type 2-Quantification, Applied
Biosystems, Lisseu, France) was performed. Each extrac-
tion and qPCR plate included negative controls (diethyl-
pyrocarbonate [DEPC]-treated water) and each sample
reaction had an internal positive control to monitor DNA
extraction and amplification procedures.
PCV-2 qPCR results were transformed as follows:
– Undetermined results and those below LOD
(LOD = 103.50 PCV-2 genome copies/mL) were
transformed as log10 (0 + 1).
– Results between LOD and LOQ (LOQ = 104.00 PCV-
2 genome copies/mL) were transformed following
the method proposed by Croghan et al. [47], where
the result was calculated as log10 ((LOQ/√2) + 1).
Therefore, the imputed value was log10 (7071 + 1).
– Results over LOQ were transformed as log10 (PCV-2
genome copies/mL + 1).
PCV-2 antibody detection by ELISA
PCV-2 antibodies in sows were detected at the three
vaccine/PBS application times as well as at farrowing
using the ELISA kit Ingezim Circo IgG/IgM 11.PCV.K2®
assay (Ingenasa, Madrid, Spain). ELISA results were
expressed as mean OD (± SD) according to the kit
instructions.
PCV-2 antibodies in piglets at weaning were detected
using the ELISA kit Ingezim Circo IgG 11.PCV.K1® assay
(Ingenasa, Madrid, Spain). Mean positive cut-off was
established as OD of negative control + 0.25). ELISA re-
sults from piglets were expressed as S/P ratio (OD of
sample / OD of positive control for each ELISA plate)
following the manufacturer’s recommendations.
PCV-2 ORF2 amplification and sequencing
Capsid protein gene (ORF2) was sequenced from PCV-2
qPCR positive sow serum and PUC samples to deter-
mine the PCV-2 genotype/s circulating in the farm.
DNA was extracted from serum samples by using the
MagMax™ Pathogen RNA/DNA Kit (Thermo Fischer
Scientific Baltics. Vilnius, Lithuania) following the manu-
facturer’s instructions.
PCV-2 Cap gene was amplified from nucleotide 1050
to 1735 (PCV-2 genome; GenBank Accession Number:
AY181948) using the primers PCV-2all_F (5′ GGGTCT
TTAAGATTAAATYC 3′) and PCV-2all_R (5′ ATGA
CGTATCCAAGGAG 3′) [48]. PCR was performed in a
25 μL reaction containing 5 μL of PCR Promega buffer,
2.5 μL of 25Mm MgCl2, 1.25 μL of each primer at 10
pmol/μL, 1 μL of 5 mM dNTPs, 0.15 U of Taq DNA
polymerase, 11.35 μL of DEPC-treated water and 2.5 μL
of extracted DNA. The PCR was performed with the fol-
lowing program: denaturation of 5 min at 94 °C, 40 cy-
cles of 30 s at 95 °C for denaturation, 30 s at 53 °C for
primer annealing and 40 s at 72 °C for elongation, with a
final elongation of 7 min at 72 °C. Amplified DNA was
confirmed by electrophoresis gel with 2% agarose.
NucleoSpin Gel and PCR Clean-up kit (Macherey–
Nagel, GmbH & Co. KG, Dueren, Germany) was used to
purify the PCR product. BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA,
USA) and 3130 × l Genetic Analyser (Applied Biosys-
tems, Ohio, USA) was used to perform the sequencing
reaction and the analysis, respectively [48]. Sequences
were edited and assembled by using ChromasPro Ver-
sion 2.1.8 (Technelysium). The sequences obtained were
submitted to the GenBank with the following accession
numbers MT572494-MT572497).
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PCV-2 capsid ProteinG (ORF2) phylogenetic and sequence
analysis
To genotype the PCV-2 sequences obtained, an align-
ment with 18 representative sequences from genotypes
PCV-2a, b, c and d was carried out with Clustal Omega
(EMBL-EBI). The phylogenetic tree was created by using
the Maximum Likelihood method included in Mega-X
software [49]. The best substitution model according
with the Bayesian information criterion was the
Hasegawa-Kishino-Yano model, with a discrete Gamma
distribution. Bootstrap resampling test was carried out
with 1000 replicates. Bootstrap values higher than 70
were indicated in the constructed phylogenetic tree.
Statistical analyses
Statistical analyses were carried out using the software
NCSS (Kaysville, Utah, USA). Comparisons were per-
formed in two ways: 1) all V groups (mimicking a blan-
ket fashion PCV-2 vaccination) versus the NV group,
and 2) all experimental groups among them.
When comparison was performed between V and NV
groups Mann-Whitney U test was used to total born
piglets per sow, live born piglets per sow, weaned piglets
per sow, weaning-to-mate interval, weaning-to-
fecundation interval, PCV-2 viral load in sera of sows as
well as viral load in PUC. Chi-square test was used to
compare proportions of abortions, mummified fetuses,
stillbirth piglets, dead suckling piglets, cross-fostered
piglets, as well as of viraemic sows and PUC. The T –
test was used to analyse birth and weaning body weights.
When comparison was performed among all experi-
mental groups, Kruskal Wallis test (including Bonferroni
test for multiple comparison) was used to analyse total
born piglets per sow, live born piglets per sow, weaned
piglets per sow, weaning-to-mate interval, weaning-to-
fecundation interval, PCV-2 ELISA antibody values in
sow and piglets’ serum samples and viral load in sera of
sows and PUCs. Serological parameters from sows were
analysed performing only the comparison among experi-
mental groups to assess the serological effect of each
vaccination. Chi-square or Fisher’s Extact test was used
to compare proportion of abortions, mummified piglets,
stillbirth piglets, dead suckling piglets, cross-fostered
piglets, as well as of viraemic sows and PUCs. Moreover,
ANOVA (including Tukey-Kramer multiple comparison
test) was used to compare birth and weaning body
weights.
The significance level (α) was set at p ≤ 0.05, whereas
statistical tendencies were reported when p ≤ 0.10.
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